Viewing nowEntiksajeong 5 mg (Memantine Hydrochloride)
Memantine Hydrochloride 5mg
Tablet · Prescription medication
Selvion Co., Ltd.

MFDS item code 202503271 · Approved 2025.12.15
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease. It helps improve memory decline and cognitive function deterioration caused by Alzheimer's disease. Treatment is expected to enhance the patient’s ability to perform daily activities and suppress symptom progression. Therefore, it is effectively used for symptomatic management in patients with moderate to severe Alzheimer's disease.
This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Day 1–7): Administer 5mg once daily for 7 days. Week 2 (Day 8–14): Administer 10mg once daily for 7 days. Week 3 (Day 15–21): Administer 15mg once daily for 7 days. From Week 4 onward, administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for older patients aged 65 years and older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since data on the use of memantine in patients with severe hepatic impairment are unavailable, it is preferable not to administer this medicine.
This medication should not be used in certain patients. For instance, individuals who have had an allergic reaction to this medication should not take it. Additionally, patients with severely impaired liver function or very poor kidney function should avoid this medication. Caution is needed when using this medication. Patients with epilepsy or those who have had seizures in the past should use this medication carefully. Also, it should not be taken with similar acting drugs such as amantadine, ketamine, or dextromethorphan, as this may worsen side effects. Patients with dietary changes that may increase urine acidity (pH) or certain urinary tract infections should be cautious. Those with uncontrolled heart disease or hypertension should consult a physician before using this medication. Side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur during treatment. Most are mild or moderately severe, and serious side effects are rare but should be monitored closely. This drug may interact with other medications. Particularly, when taken with levodopa, dopamine agonists, or anticholinergics, the effects or side effects may change. It may also reduce the effectiveness of barbiturates or antipsychotics, and when combined with skeletal muscle relaxants, dosage adjustment may be necessary. Women who are pregnant or may become pregnant should weigh the benefits and risks before taking this medication, and breastfeeding mothers are recommended to discontinue nursing. Children and adolescents under 18 years should not use this medication, as its safety and effectiveness have not been established. In the case of overdose, symptoms may include drowsiness, confusion, dizziness, diarrhea, and in severe cases, psychiatric symptoms or seizures may occur. In such situations, immediate medical attention is required. Finally, this medication may affect the patient's reaction speed, so caution is advised when operating a vehicle or machinery. This medication should be stored out of reach of children, and transferring it to another container is not recommended for quality maintenance.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to protect it from air and moisture. It should also be stored at room temperature, ideally between 1 to 30 degrees Celsius, avoiding excessive heat or cold.
White oval film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 5mg
Tablet · Prescription medication
Selvion Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.